Genovis’ project for automatic analysis with the FabRICATOR® enzyme shows proof-of-concept

Genovis’ project to develop automated analysis solutions together with researchers from Lund Institute of Technology has reached the proof-of-concept stage, which now must be verified by a number of major industrial players.

“The results are important for Genovis since they clearly show commercial potential for FabRICATOR® (IdeS) in integrated analysis systems. It is mainly in quality control in the development and production of biopharmaceuticals that the system offers major advantages over current methods. We can see that in the long run this will open up a new market for Genovis’ FabRICATOR® enzyme,” says Sarah Fredriksson, CEO.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00